As an early funder of Capricor Therapeutics, CureDuchenne is pleased to share that the FDA has set the PDUFA target action date for August 22, 2026 as the deadline to review approval of deramiocel for Duchenne muscular dystrophy. Deramiocel is a cell therapy that exerts immunomodulatory and anti-fibrotic actions on cardiac and skeletal muscle.
Read press release here: https://www.capricor.com/investors/news-events/press-releases/detail/338/capricor-therapeutics-announces-establishment-of-new-pdufa
The post Capricor announces the FDA to review deramiocel for Duchenne by August 2026 appeared first on CureDuchenne.